labetalol has been researched along with Heart Failure in 21 studies
Labetalol: A salicylamide derivative that is a non-cardioselective blocker of BETA-ADRENERGIC RECEPTORS and ALPHA-1 ADRENERGIC RECEPTORS.
labetalol : A diastereoisomeric mixture of approximately equal amounts of all four possible stereoisomers ((R,S)-labetolol, (S,R)-labetolol, (S,S)-labetalol and (R,R)-labetalol). It is an adrenergic antagonist used to treat high blood pressure.
2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide : A member of the class of benzamides that is benzamide substituted by a hydroxy group at position 2 and by a 1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl group at position 5.
Heart Failure: A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We investigated the effects of the beta1-beta2-alpha1-blocker, labetalol, in the congestive heart failure (CHF) model induced by aortic constriction in the guinea pig." | 7.71 | Early anti-remodeling effect of labetalol in the congestive heart failure model induced by aortic constriction in the guinea pig. ( Bellissant, E; Goineau, S; Guillo, P; Pape, D; Ramée, MP, 2002) |
| "Labetalol is used to treat hypertensive crisis in women with preeclampsia." | 7.69 | Use of glucagon to treat neonatal low-output congestive heart failure after maternal labetalol therapy. ( Guillet, R; Stevens, TP, 1995) |
| "To investigate the safety of labetalol in the treatment of hypertension in patients with heart failure, sixteen hypertensive patients with a history of congestive heart failure and an ejection fraction at rest less than 45%, had measurements of ejection fraction and cardiac output by first pass radionuclide angiography at baseline, at the end of 2 weeks maintenance with labetalol (titrated to the effective antihypertensive dose of 200-1600 mg daily), and in the post-treatment placebo period." | 7.67 | Hemodynamic effects of labetalol in patients with combined hypertension and left ventricular failure. ( Berger, H; Cubbon, J; Escala, E; Johnson, LL; Jones, RH; Ramanathan, KB; Sciacca, R, 1988) |
| " Oral nifedipine is now considered an alternative first-line therapy, along with intravenous hydralazine and labetalol for women presenting with pre-eclampsia." | 4.98 | Focused Update on Pharmacologic Management of Hypertensive Emergencies. ( Broscious, R; Devabhakthuni, S; Noel, ZR; Watson, K, 2018) |
| " It has also been used intravenously in phaeochromocytoma, tetanus, clonidine withdrawal, and as an adjunct to halothane to produce hypotensive anaesthesia." | 4.76 | Combined alpha- and beta-receptor inhibition in the treatment of hypertension. ( Prichard, BN, 1984) |
| "We investigated the effects of the beta1-beta2-alpha1-blocker, labetalol, in the congestive heart failure (CHF) model induced by aortic constriction in the guinea pig." | 3.71 | Early anti-remodeling effect of labetalol in the congestive heart failure model induced by aortic constriction in the guinea pig. ( Bellissant, E; Goineau, S; Guillo, P; Pape, D; Ramée, MP, 2002) |
| "Labetalol is used to treat hypertensive crisis in women with preeclampsia." | 3.69 | Use of glucagon to treat neonatal low-output congestive heart failure after maternal labetalol therapy. ( Guillet, R; Stevens, TP, 1995) |
| "To investigate the safety of labetalol in the treatment of hypertension in patients with heart failure, sixteen hypertensive patients with a history of congestive heart failure and an ejection fraction at rest less than 45%, had measurements of ejection fraction and cardiac output by first pass radionuclide angiography at baseline, at the end of 2 weeks maintenance with labetalol (titrated to the effective antihypertensive dose of 200-1600 mg daily), and in the post-treatment placebo period." | 3.67 | Hemodynamic effects of labetalol in patients with combined hypertension and left ventricular failure. ( Berger, H; Cubbon, J; Escala, E; Johnson, LL; Jones, RH; Ramanathan, KB; Sciacca, R, 1988) |
| "A patient treated for hypertension with labetalol developed left ventricular failure." | 3.66 | Left ventricular failure with labetalol. ( Bayley, TJ; Frais, MA, 1979) |
| " Hepatic pharmacokinetic modelling was performed with a two-phase physiologically-based organ pharmacokinetic model with the vascular space and dispersion evaluated with the MID technique." | 1.38 | Hepatocellular necrosis, fibrosis and microsomal activity determine the hepatic pharmacokinetics of basic drugs in right-heart-failure-induced liver damage. ( Crawford, DH; Fletcher, LM; Li, P; Roberts, MS; Robertson, TA; Weiss, M; Zhang, Q, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (42.86) | 18.7374 |
| 1990's | 2 (9.52) | 18.2507 |
| 2000's | 5 (23.81) | 29.6817 |
| 2010's | 4 (19.05) | 24.3611 |
| 2020's | 1 (4.76) | 2.80 |
| Authors | Studies |
|---|---|
| Zhou, H | 1 |
| Sim, JJ | 1 |
| Shi, J | 1 |
| Shaw, SF | 1 |
| Lee, MS | 2 |
| Neyer, JR | 1 |
| Kovesdy, CP | 1 |
| Kalantar-Zadeh, K | 1 |
| Jacobsen, SJ | 1 |
| Duan, L | 1 |
| Ng, A | 1 |
| Chen, W | 1 |
| Spencer, HT | 1 |
| Nguyen, J | 1 |
| Shen, AY | 1 |
| Watson, K | 1 |
| Broscious, R | 1 |
| Devabhakthuni, S | 1 |
| Noel, ZR | 1 |
| Jacobson, AF | 1 |
| Travin, MI | 1 |
| Manrique, C | 1 |
| Giles, TD | 1 |
| Ferdinand, KC | 1 |
| Sowers, JR | 1 |
| Li, P | 1 |
| Robertson, TA | 1 |
| Zhang, Q | 1 |
| Fletcher, LM | 1 |
| Crawford, DH | 1 |
| Weiss, M | 1 |
| Roberts, MS | 1 |
| Kai, H | 1 |
| Imaizumi, T | 2 |
| Weber, MA | 1 |
| Mizuta, Y | 1 |
| Rubin, PC | 1 |
| Reid, JL | 1 |
| Prichard, BN | 1 |
| Bernard, R | 1 |
| Renard, M | 1 |
| El Matri, A | 1 |
| Kechrid, C | 1 |
| Larabi, M | 1 |
| Belkahia, C | 1 |
| Ben Ayed, H | 1 |
| Cohn, JN | 1 |
| Mehta, J | 1 |
| Francis, GS | 1 |
| Stevens, TP | 1 |
| Guillet, R | 1 |
| Pape, D | 1 |
| Goineau, S | 1 |
| Guillo, P | 1 |
| Ramée, MP | 1 |
| Bellissant, E | 1 |
| Frishman, W | 1 |
| Halprin, S | 1 |
| Frais, MA | 1 |
| Bayley, TJ | 1 |
| Strein, K | 1 |
| Sponer, G | 1 |
| Johnson, LL | 1 |
| Cubbon, J | 2 |
| Escala, E | 1 |
| Sciacca, R | 1 |
| Ramanathan, KB | 1 |
| Berger, H | 1 |
| Jones, RH | 1 |
| Kinhal, V | 1 |
| Kulkarni, A | 1 |
| Pozderac, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Alternative in Beta Blocker Intolerance; the ABBI Trial[NCT00893984] | Phase 4 | 6 participants (Actual) | Interventional | 2009-05-31 | Terminated (stopped due to Lack of patient recruitment) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00893984)
Timeframe: 30 Days
| Intervention | Participants (Count of Participants) |
|---|---|
| Nebivolol | 0 |
(NCT00893984)
Timeframe: 30 Days
| Intervention | Participants (Count of Participants) |
|---|---|
| Nebivolol | 0 |
Mild symptoms include weight gain, edema, and headaches (NCT00893984)
Timeframe: 30 Days
| Intervention | participants (Number) |
|---|---|
| Nebivolol | 1 |
(NCT00893984)
Timeframe: 30 Days
| Intervention | Participants (Count of Participants) |
|---|---|
| Nebivolol | 0 |
8 reviews available for labetalol and Heart Failure
| Article | Year |
|---|---|
Focused Update on Pharmacologic Management of Hypertensive Emergencies.
Topics: Administration, Oral; Antihypertensive Agents; Blood Pressure; Brain Ischemia; Emergencies; Enalapri | 2018 |
Impact of medications on mIBG uptake, with specific attention to the heart: Comprehensive review of the literature.
Topics: 3-Iodobenzylguanidine; Amines; Amiodarone; Animals; Anti-Arrhythmia Agents; Antidepressive Agents, T | 2015 |
Realities of newer beta-blockers for the management of hypertension.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Benzopyrans; Carbazoles; Carvedilol; Ethanolam | 2009 |
[Protective effect of alpha beta-blockers on hypertensive target-organ damage].
Topics: Adrenal Gland Neoplasms; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Antihypertensive | 2004 |
The role of the new beta-blockers in treating cardiovascular disease.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Atenolol; Benzopyrans | 2005 |
[Alpha beta-blockers for patients with hypertension].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Antihypertensive Agents; Carbazoles; Carv | 2006 |
Combined alpha- and beta-receptor inhibition in the treatment of hypertension.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Anesthesia; Antihyp | 1984 |
Experimental and clinical pharmacology of carvedilol and other drugs combining vasodilation and beta-adrenoceptor antagonism in a single molecule.
Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Celiprolol; Coronary Disease; Heart Fa | 1990 |
1 trial available for labetalol and Heart Failure
| Article | Year |
|---|---|
Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 7. New horizons in beta-adrenoceptor blockade therapy: labetalol.
Topics: Arrhythmias, Cardiac; Chemical Phenomena; Chemistry; Clinical Trials as Topic; Coronary Disease; Eth | 1979 |
12 other studies available for labetalol and Heart Failure
| Article | Year |
|---|---|
β-Blocker Use and Risk of Mortality in Heart Failure Patients Initiating Maintenance Dialysis.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Atenolol; Bisoprolol; Carvedilol; Cause of Dea | 2021 |
β-Blocker Exposure in Pregnancy and Risk of Fetal Cardiac Anomalies.
Topics: Adrenergic beta-Antagonists; Age Factors; Arrhythmias, Cardiac; Atenolol; Body Mass Index; Californi | 2017 |
Hepatocellular necrosis, fibrosis and microsomal activity determine the hepatic pharmacokinetics of basic drugs in right-heart-failure-induced liver damage.
Topics: Adrenergic Antagonists; Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti | 2012 |
Alpha-blockers and converting enzyme inhibitors.
Topics: Adrenergic alpha-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Captopril; Heart Failure; Hu | 1983 |
[Heart failure and acute myocardial infarct. Current treatment].
Topics: Cardiotonic Agents; Dobutamine; Heart Failure; Humans; Imidazoles; Labetalol; Myocardial Infarction; | 1983 |
[Combined captopril and labetalol treatment of malignant arterial hypertension (author's transl)].
Topics: Adult; Captopril; Drug Synergism; Drug Therapy, Combination; Ethanolamines; Female; Heart Failure; H | 1981 |
A review of the haemodynamic effects of labetalol in man.
Topics: Blood Pressure; Ethanolamines; Heart Failure; Heart Rate; Hemodynamics; Humans; Hypertension; Labeta | 1982 |
Use of glucagon to treat neonatal low-output congestive heart failure after maternal labetalol therapy.
Topics: Adult; Eclampsia; Female; Glucagon; Heart Failure; Humans; Infant, Newborn; Infant, Newborn, Disease | 1995 |
Early anti-remodeling effect of labetalol in the congestive heart failure model induced by aortic constriction in the guinea pig.
Topics: Adrenergic beta-Antagonists; Animals; Aorta; Aortic Valve Stenosis; Body Weight; Disease Models, Ani | 2002 |
Left ventricular failure with labetalol.
Topics: Adult; Ethanolamines; Heart Diseases; Heart Failure; Humans; Hypertension; Labetalol; Male | 1979 |
Hemodynamic effects of labetalol in patients with combined hypertension and left ventricular failure.
Topics: Angiography; Cardiac Output; Exercise Test; Female; Heart Failure; Hemodynamics; Humans; Hypertensio | 1988 |
Hemodynamic effects of dilevalol in patients with systemic hypertension and left ventricular dysfunction.
Topics: Aged; Exercise Test; Heart Failure; Heart Rate; Hemodynamics; Humans; Hypertension; Labetalol; Male; | 1989 |